NCT03115762View on ClinicalTrials.gov

Pharmacokinetics and Safety Study of ASKB1202 in Chinese Healthy Subjects

PHASE1UnknownINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

June 30, 2017

Primary Completion Date

July 31, 2017

Study Completion Date

July 31, 2017

Conditions
Healthy
Interventions
BIOLOGICAL

bevacizumab

recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells

BIOLOGICAL

ASKB1202

Sponsors
All Listed Sponsors
lead

Jiangsu Aosaikang Pharmaceutical Co., Ltd.

INDUSTRY